<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurol Neuroimmunol Neuroinflamm</journal-id><journal-id journal-id-type="iso-abbrev">Neurol Neuroimmunol Neuroinflamm</journal-id><journal-id journal-id-type="hwp">nnn</journal-id><journal-id journal-id-type="publisher-id">NEURIMMINFL</journal-id><journal-title-group><journal-title>Neurology&#x000ae; Neuroimmunology &#x00026; Neuroinflammation</journal-title></journal-title-group><issn pub-type="epub">2332-7812</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31848230</article-id><article-id pub-id-type="pmc">6943366</article-id><article-id pub-id-type="publisher-id">NEURIMMINFL2019023820</article-id><article-id pub-id-type="doi">10.1212/NXI.0000000000000652</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>14</subject><subject>38</subject><subject>132</subject><subject>137</subject><subject>205</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sola-Valls</surname><given-names>Nuria</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>Dr. Sola-Valls received speaking honoraria from Sanofi, Bayer-Schering, Novartis and Biogen-Idec.</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>N Sola Valls receives funding from the Instituto de Salud Carlos III, Spain and Fondo Europeo de Desarrollo Regional (FEDER) (FI16/00251), Predoctoral Grant for Health Research (PFIS)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Ari&#x000f1;o</surname><given-names>Helena</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Escudero</surname><given-names>Domingo</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Solana</surname><given-names>Elisabeth</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Llad&#x000f3;</surname><given-names>Albert</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;nchez-Valle</surname><given-names>Raquel</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>IONIS. Wave pharmaceuticals</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Journal of Alzheimer's disease</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>PI16/0235 ISCIII-Spain</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Blanco</surname><given-names>Yolanda</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Saiz</surname><given-names>Albert</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>compensation for consulting services and speaker honoraria from Bayer-Schering, Merck-Serono, Biogen-Idec, Sanofi-Aventis, Teva Pharmaceutical Industries Ltd, Novartis, and Roche</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Dalmau</surname><given-names>Josep</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Neurology, Neuroimmunology and Neuroinflammation Neurology UpToDate</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>Advance Medical</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>-NIH, RO1NS077851, PI, 2011-2018 -Instituto Carlos III/FEDER (FIS, 14/00203 and CIBERER CB15/00010, and Proyectos Integrados de Excelencia, PIE 16/00014). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya -ERA-NET Neuron</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Safra Foundation Sage therapeutics Cellex Foundation La Caixa Health Foundation</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License fee payments, Technology or Inventions:</title><list-item><p>NMDA receptor autoantibody test/Euroimmun GABA(B)R autoantibody test/Euroimmun GABA(A)R autoantibody test/Euroimmun DPPX autoantibody test/Euroimmun Iglon5 autoantibody test/Euroimmun</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>Patent Ma2 autoantibody test Patent NMDAR autoantibody test Patent GABA(B) receptor autoantibody test Patent application for the use of GABA(A) receptor, DPPX and IgLON5 autoantiboddy tests</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Graus</surname><given-names>Francesc</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Assistant Editor MedLink Neurology</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>licensing fee from Euroimmun for the use of IgLON5 as an autoantibody test</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigaci&#x000f3; Biom&#x000e8;dica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Cl&#x000ed;nic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Instituci&#x000f3; Catalana de Recerca i Estudis Avan&#x000e7;ats (ICREA) (J.D.), Barcelona, Spain.</aff></contrib-group><author-notes><corresp><bold>Correspondence</bold> Dr. Graus <email>francesc.graus@idibaps.org</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="https://nn.neurology.org/content/7/2/e652/tab-article-info">Neurology.org/NN</ext-link> for full disclosures. Funding information is provided at the end of the article.</p></fn><fn fn-type="other"><p>The Article Processing Charge was funded by the authors.</p></fn></author-notes><pub-date pub-type="collection"><month>3</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>12</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>7</volume><issue>2</issue><elocation-id>e652</elocation-id><history><date date-type="received"><day>03</day><month>9</month><year>2019</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEURIMMINFL2019023820.pdf"/><abstract><sec><title>Objective</title><p>To assess the feasibility of a structured telephone interview examining the long-term cognitive and functional status in anti&#x02013;leucine-rich, glioma-inactivated 1 (LGI1) encephalitis.</p></sec><sec><title>Methods</title><p>Telephone interviews were conducted with 37 patients after a median follow-up of 87 months from disease onset and 23 healthy controls matched for age and sex. Cognitive status was assessed with the telephone Mini-Mental State Examination (t-MMSE) and 3 tests exploring verbal memory, fluency, and executive function. Functional status was evaluated with the Functional Activities Questionnaire and the modified Rankin Scale (mRS). Patients were classified as normal, with mild cognitive impairment (MCI), or with dementia based on cognitive and functional status. Assessment of the cognitive reserve was performed with a structured questionnaire. Logistic regression analysis was applied to identify predictors of cognitive impairment.</p></sec><sec><title>Results</title><p>Telephone interviews were successful in 36/37 (97%) patients. Cognitive impairment was detected in 27 (75%) including 17 with MCI and 10 with dementia. Eight (29%) patients would have been misclassified using only the t-MMSE. Twenty-six (72%) patients were functionally independent according to the mRS, but only 9 (35%) were cognitively normal. Independent predictors for long-term cognitive impairment were a low cognitive reserve (OR = 1.36, 95% CI: 1.05&#x02013;1.76; <italic>p</italic> = 0.02) and bilateral hippocampal hyperintensity at initial MRI (OR = 27.03, 95% CI: 1.87&#x02013;390; <italic>p</italic> = 0.02).</p></sec><sec><title>Conclusions</title><p>Telemedicine is a feasible tool to assess the cognitive and functional outcome in patients with anti-LGI1 encephalitis. Cognitive impairment is often missed if only functional scales are used. Premorbid cognitive reserve and MRI with bilateral hippocampal hyperintensity were predictors for long-term cognitive impairment.</p></sec></abstract><funding-group><award-group><funding-source>Fondo de Investigaciones Sanitarias and Fondo Europeo de Desarrollo Regional</funding-source><award-id>FIS 15/00377, FG; FIS 14/00203, J.D.</award-id></award-group><award-group><funding-source>NIH</funding-source><award-id>RO1NS077851</award-id></award-group><award-group><funding-source>Predoctoral Grant for Health Research</funding-source><award-id>FI16/00251</award-id></award-group><award-group><funding-source>Instituto de Salud Carlos III</funding-source><award-id>CM16/00136</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Anti&#x02013;leucine-rich, glioma-inactivated 1 (LGI1) encephalitis is the second most frequent autoimmune encephalitis with an estimated annual incidence of 0.83 cases per million.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Patients with LGI1 antibodies develop subacute onset of memory impairment, behavioral changes, and hyponatremia. The encephalitic phase is frequently preceded by a variable period where patients have isolated seizures including, among others, faciobrachial dystonic seizures.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> Symptoms usually respond to corticosteroids, and nearly 70% of patients have good functional recovery. However, only a third of patients return to their baseline premorbid status.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup></p><p>Clinical assessment using only functional scales, such as the modified Rankin Scale (mRS) score, may overlook cognitive deficits that limit the return to previous activities and affect quality of life. However, studies that evaluate cognitive outcome in anti-LGI1 encephalitis are scarce and do not go beyond 2 years of follow-up. Previous research suggested that patients showed a marked impairment on memory, executive function, and processing speed at presentation, whereas some patients remained with residual deficits mainly observed on verbal memory.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R4" ref-type="bibr">4</xref><xref ref-type="bibr" rid="R5">&#x02013;</xref><xref rid="R7" ref-type="bibr">7</xref></sup> In addition, the role of premorbid cognitive reserve that probably is relevant in the recovery of elderly patients after acute neurologic events has not been previously explored in cases of anti-LGI1 encephalitis.<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p><p>Telemedicine is a novel discipline that offers high-quality patient care through numerous applications and services that facilitate a direct, cost-effective exchange of information between patients and physicians.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> In the case of rare diseases or patients' with restricted access to subspecialty care, such as autoimmune encephalitis, the use of telemedicine may be useful to assess cognitive performance in more detail over time.<sup><xref rid="R10" ref-type="bibr">10</xref></sup></p><p>In this study, we assessed the feasibility of using a structured telephone interview to examine long-term cognitive performance and functional status of patients with anti-LGI1 encephalitis.</p><sec sec-type="methods" id="s1"><title>Methods</title><sec id="s1-1"><title>Patients</title><p>We reviewed all Spanish patients with anti-LGI1 encephalitis diagnosed at the Neuroimmunology laboratory of the Institut d'Investigaci&#x000f3; Biom&#x000e8;dica August Pi i Sunyer (IDIBAPS), Hospital Clinic (Barcelona, Spain), between September 1998 and June 2014. Patients were included if they fulfilled the following criteria: (1) age &#x02265;18 years; (2) evidence of cognitive deterioration at diagnosis demonstrated by direct patient examination by one of the authors or provided by the referring physicians through a structured written questionnaire; and (3) minimum clinical follow-up of 4 years. We initially identified 49 patients, and 37 were finally included in the study. Reasons for exclusion were death (7 patients, 2 of them with dementia), severe dementia that precluded the telephone interview (3), and lost to follow-up (2). All 37 patients were invited by their referring physicians to participate in the study. After the patient's agreement to participate, one of the authors contacted the patient directly to explain the goals of the study and obtain informed verbal consent, witnessed by a relative. Appointments for the structured telephone interview were scheduled according to dates and times that were convenient for patients and relatives. Information on symptom onset and main syndromes, ancillary studies, treatment response to immunotherapy, and functional outcome at 24 months was previously reported.<sup><xref rid="R3" ref-type="bibr">3</xref></sup></p></sec><sec id="s1-2"><title>Telephone intervention characteristics</title><p>Each telephone interview was performed by the same neurologist (N.S.) and lasted approximately 60 minutes. This included a structured interview with the patient about current clinical status, presence of comorbidities,<sup><xref rid="R11" ref-type="bibr">11</xref></sup> the cognitive reserve questionnaire, and the Functional Activities Questionnaire (FAQ). Patients answered all the questions, and the answers were corroborated by a family member. The cognitive reserve questionnaire measured 8 different aspects of the premorbid intellectual activity (educational level and training courses, educational level of parents, work occupation performed throughout life, musical education, and ability to speak several languages) and cognitive-stimulating activities such as reading and practicing intellectual games (<xref rid="T1" ref-type="table">table 1</xref>). The final score was the sum of the scores for each item (maximum 25 points, best cognitive reserve).<sup><xref rid="R12" ref-type="bibr">12</xref></sup> The FAQ is a standardized assessment of instrumental activities of daily living (11 items). Functional dependence is considered with scores &#x02265;6 points.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> Based on the aforementioned data, the mRS score was obtained, as this is the most widely used clinical outcome for measuring the degree of disability or dependence of patients with neurologic disability. The mRS is an ordered scale coded from 0 (no symptoms) through 5 (severe disability) and 6 (death). This scale has been shown to be reliable when obtained by telephone, and the Spanish version has been previously validated. Bad functional outcome was defined when the mRS score was &#x02265;3.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup></p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Cognitive reserve questionnaire<sup><xref rid="R12" ref-type="bibr">12</xref></sup></p></caption><graphic xlink:href="NEURIMMINFL2019023820t1"/><graphic xlink:href="NEURIMMINFL2019023820t1a"/></table-wrap><p>Before starting the brief cognitive battery, the family member was asked to leave the room and remove any calendars, clocks, or devices that could interfere with the cognitive evaluation. The brief cognitive battery comprised the Spanish telephone version of the Mini-Mental State Examination (t-MMSE) and evaluation of 3 specific cognitive domains: verbal memory, executive function, and language. The Spanish version of the t-MMSE score ranges from 0 to 26, and cognitive impairment is defined when the score is &#x02264;21 points.<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> Verbal memory was evaluated using the Free and Cued Selective Reminding Test modified from Buschke.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Briefly, this test consists of one immediate recall task in which participants have to recall as many as 16 words (first free and then using a semantic clue) and a delayed recall task after 30 minutes. Only the delayed recall score (the sum of free and facilitated) was used for the memory index, as this score was highly correlated with the immediate recall score in our study population (list recall: rho = 0.84, <italic>p</italic> &#x0003c; 0.001). Executive function was assessed using the oral Trial Making Test A and B.<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> In this test, participants are asked to count from 1 to 25 as quickly as possible (part A) and count again, but switching between numbers and alphabet letters until 13 (part B). The final score is the time in seconds needed to complete task B. Language was explored evaluating the verbal fluency asking the participants to say as many words as possible in 1 minute from a semantic category (e.g., fruits and vegetables), and the final score was the total number of words provided.</p><p>The brief cognitive battery was initially tested in a group of 23 healthy controls to ensure the feasibility to perform it by telephone and to obtain reference values for the cognitive tests. Controls had a median age of 74 years (interquartile range [IQR], 64&#x02013;80) and 9 (39%) were male. No significant difference was observed in demographic variables or educational level between patients and healthy controls. To compare the cognitive performance across patients, raw scores from individual tests were converted to z-scores. Mild cognitive impairment (MCI) was considered when one or more cognitive domains showed a z-score below &#x02212;1.5 SD of the healthy controls' distribution without interference in the activities of daily living.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> Dementia was considered when these cognitive changes had a negative impact on the activities of daily living.</p><p>At the end of the telephone interview, all participants were assessed by the Hospital Anxiety and Depression Scale (score &#x02265;11 points identified patients with mood disturbances) and the Pittsburgh Sleep Quality Index questionnaire (a score &#x02265;6 points was indicative of poor quality of sleep).<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> Participants were also verbally assessed with the five-level version of the EuroQoL-5 dimensions instrument, which measures health-related quality of life. This instrument comprises the European quality (EQ) index value divided into 5 dimensions (mobility, self-care, usual activities, pain/complaints, and anxiety/depression) and the visual analog score (EQ-VAS).<sup><xref rid="R25" ref-type="bibr">25</xref></sup></p></sec><sec id="s1-3"><title>Standard protocol approvals, registrations, and patient consents</title><p>The ethics committees of the Hospital Clinic approved the study. All patients or proxies gave written informed consent for the storage and use of serum, CSF, and clinical information for research purposes. All patients and healthy controls gave consent to participate in the telephone interview.</p></sec><sec id="s1-4"><title>Statistics</title><p>Descriptive statistics were computed as median (IQR) unless otherwise noted. Differences among groups based on cognitive performance were studied using the &#x003c7;<sup>2</sup> test and Mann-Whitney <italic>U</italic> test as convenient, with a significance level set to <italic>p</italic> &#x0003c; 0.05). Binary logistic regression was performed to identify predictors of cognitive impairment (MCI and dementia). Accuracy of the potential predictive value of clinical variables to detect patients with cognitive impairment was analyzed by the area under the curve (AUC). Statistical analyses were performed using SPSS version 25.0 (SPSS Inc, Chicago, IL) software.</p></sec><sec sec-type="data-availability" id="s1-5"><title>Data availability</title><p>Data from the patients reported within the article are available and will be shared anonymously by request from any qualified investigator.</p></sec></sec><sec sec-type="results" id="s2"><title>Results</title><sec id="s2-1"><title>Feasibility of telephone intervention and demographic characteristics</title><p>The telephone interview was successful in 36/37 (97%) patients. Only one patient complained about the length of the interview before starting the brief telephone cognitive battery and did not agree to continue. Clinical and demographic features of the 36 patients are summarized in <xref rid="T2" ref-type="table">table 2</xref>. The median age at diagnosis was 65 years (IQR: 56&#x02013;74 years), and 23 (64%) were male. At the time of diagnosis of anti-LGI1 encephalitis, patients had a median mRS score of 4 (IQR: 3&#x02013;4). All patients were treated with first-line immunotherapy (steroids &#x000b1; IV immunoglobulin), and 18 (50%) also received second-line (11) or chronic (7) immunotherapy. At 2 years, 28 (78%) were functionally independent (mRS score &#x0003c;3). At the last visit, 12 (33%) patients were still on antiepileptic drugs, but only 3 patients (8%) had experienced seizures during the preceding year.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Demographic and clinical description of 36 patients with anti-LGI1 encephalitis who completed the telephone interview</p></caption><graphic xlink:href="NEURIMMINFL2019023820t2"/></table-wrap></sec><sec id="s2-2"><title>Long-term cognitive and functional status</title><p>Long-term evaluation of patients was analyzed after a median follow-up of 87 months (IQR: 63&#x02013;136 months). Patients performed significantly worse in all cognitive tests compared with healthy controls (<xref rid="T3" ref-type="table">table 3</xref>), and 27/36 (75%) were considered to have cognitive impairment that was classified as MCI in 17 (63%) and dementia in 10 (37%). The t-MMSE and the assessment of specific cognitive domains showed moderate agreement in the detection of cognitive impairment (kappa coefficient = 0.54; 95% CI: 0.30&#x02013;0.78; <italic>p</italic> &#x0003c; 0.001). Nineteen of the 36 (53%) patients were considered cognitive impaired using t-MMSE and the assessment of specific cognitive domains, and 8 (29%) of 27 patients were classified as MCI by the brief cognitive battery despite performing well on the t-MMSE. In contrast, none of the patients who performed well in the cognitive evaluation had a low score in the t-MMSE. Patients with dementia showed worse results in executive functioning and verbal fluency compared with patients with MCI (<italic>p</italic> &#x0003c; 0.001 in both domains) (<xref ref-type="fig" rid="F1">figure</xref>). Overall, the most frequently affected cognitive domain was verbal fluency (N = 19, 53%), followed by verbal memory (N = 18, 50%) and executive functioning (N = 11, 31%).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Results of the brief cognitive battery and related assessments obtained by telephone interview</p></caption><graphic xlink:href="NEURIMMINFL2019023820t3"/></table-wrap><fig id="F1" orientation="portrait" position="float"><label>Figure</label><caption><title>Comparison among the z-scores of patients with anti&#x02013;leucine-rich, glioma-inactivated 1 encephalitis with normal cognitive function, mild cognitive impairment, and dementia</title><p>The graph represents the median and interquartile range of the z-score in each cognitive domain for patients with normal cognitive function (closed circle), mild cognitive impairment (closed square), and dementia (closed triangle).</p></caption><graphic xlink:href="NEURIMMINFL2019023820f1"/></fig><p>Patients showed higher degrees of anxiety and/or depression and worse sleep quality than healthy controls (<xref rid="T2" ref-type="table">table 2</xref>). Six (17%) patients had symptoms of emotional distress, and 14 (39%) referred to poor quality of sleep. Quality of life perceived by the patients was not different from that of controls with the exception of the 10 patients with dementia (median EQ-VAS score: 69% vs 80% of controls; <italic>p</italic> = 0.03).</p><p>Twenty-six of the 36 patients (72%) were considered functionally independent (FAQ &#x0003c; 6 points). Eleven of them (42.3%) were functionally normal (mRS score = 0), 4 (15.4%) had symptoms without significant disability (mRS score = 1), and 11 (42.3%) were independent but unable to perform premorbid activities (mRS score = 2). Despite the good functional status, 17/26 (65%) patients had evidence of MCI. The remaining 10 (28%) patients were functionally dependent (FAQ &#x02265; 6) with an mRS score &#x02265;3, and all had dementia.</p></sec><sec id="s2-3"><title>Predictors of long-term cognitive outcome</title><p>Compared with cognitively normal patients, the estimated premorbid cognitive reserve of the 27 patients with cognitive impairment was lower (median [IQR]: 9 [7&#x02013;13] vs 16 [9&#x02013;17] points; <italic>p</italic> = 0.02), more frequent bilateral hippocampal hyperintensity on initial MRI (67% vs 11%; <italic>p</italic> = 0.009), poor response to first-line treatment (52% vs 11%; <italic>p</italic> = 0.03), required second-line treatment (41% vs 0%; <italic>p</italic> = 0.02), and had worse an mRS score at 2 years (mRS score &#x02265;3 = 70% vs 33%; <italic>p</italic> = 0.049). No differences were observed regarding age at diagnosis, the presence of distinct clinical or paraclinical features, the delay to first-line treatment, the occurrence of relapses, or the time of follow-up. In the logistic regression analysis, including age, time of follow-up, and the existence of comorbidities as covariates, the estimated premorbid cognitive reserve (OR = 1.36, 95% CI: 1.05&#x02013;1.76, <italic>p</italic> = 0.02) and the presence of bilateral hippocampal hyperintensity at the initial MRI (OR = 27.03, 95% CI: 1.87&#x02013;390, <italic>p</italic> = 0.02) were independent predictors for long-term cognitive impairment. In fact, an estimated premorbid cognitive reserve cutoff point of 14.5 points was able to discriminate patients who developed cognitive impairment from those who did not (sensitivity 0.67, specificity 0.89, and accuracy AUC = 0.75, 95% CI = 0.53&#x02013;0.98, <italic>p</italic> = 0.03).</p></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>This study shows the advantages and feasibility of using a structured telephone interview to assess the cognitive and functional status of patients who had anti-LGI1 encephalitis. Our findings show that the outcome evaluation of autoimmune encephalitis only based on the mRS score is not optimal and often misses the detection of cognitive deficits. Concerning the long-term outcome of patients with anti-LGI encephalitis, we found that 75% had cognitive deficits, ranging from MCI to dementia, and that the estimated premorbid cognitive reserve and presence of bilateral MRI hippocampal hyperintensity at disease onset are independent predictors for long-term cognitive impairment.</p><p>The use of our structured telephone intervention provides more reliable information than that obtained only assessing the functional status according to the impression of patients' physicians or relatives, and it is particularly useful for patients with rare diseases who often come from distant geographical locations or patients whose clinical status limits follow-up visits.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> The observed moderate agreement between the t-MMSE and the cognitive battery of tests suggests that it is worth including the t-MMSE in the routine outcome assessment of autoimmune encephalitis, although it does not capture all cases with MCI (29% missed in this study). Adding the indicated cognitive battery of tests increases the length of the interview but provides relevant information on distinct cognitive functions, which may potentially be affected differently depending on the type of autoimmune encephalitis.<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p><p>As far as the evaluation of the functional status is concerned, the inclusion of the FAQ helps to confirm the mRS score. The FAQ is focused on the ability to perform the activities of daily living (e.g., preparing meals or managing personal finances) that are affected at early stages of dementia development, probably before the mRS score is affected.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Other comorbidities could affect the mRS score but not specific items of FAQ. In our study, 72% of patients had a good functional status (mRS score &#x0003c;3) after a median follow-up of 7 years. This <xref ref-type="fig" rid="F1">figure</xref> would decrease to 67% if we include the 3 patients with severe dementia that could not carry out the interview. In any case, the frequency is similar to that reported in a Dutch series (67%)<sup><xref rid="R1" ref-type="bibr">1</xref></sup> and our own series (71%)<sup><xref rid="R3" ref-type="bibr">3</xref></sup> in which the follow-up was 2 years.</p><p>Among the 26 patients who were functionally independent, only 9 (35%) had normal cognitive function emphasizing the need to include a formal cognitive evaluation to assess the full effect of anti-LGI1 encephalitis in patients' outcome. We detected lower scores in cognitive domains beyond memory deficits.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> A similar result, including visuospatial memory deficits, was identified in a series of 30 patients examined a median of 2 years after onset of anti-LGI1 encephalitis.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Another series consisting of 11 patients with a good mRS score (0&#x02013;2) who had neuropsychological assessment after a median of 44 months from disease onset showed that visuospatial recognition memory was the main residual deficit.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> This cognitive domain could not be assessed in our telephone interview, suggesting that the frequency of cognitive impairment could be even higher than that reported here.</p><p>Our study shows that a lower estimated premorbid cognitive reserve and the presence of bilateral MRI hippocampal hyperintensity at disease onset are 2 independent predictors of long-lasting cognitive impairment. Cognitive reserve is defined as the adaptability of cognitive processes to brain aging, pathology, or insult. It is influenced by innate individual differences and the exposure to different socio-occupational factors such as early life education, profession, leisure activities, and/or social engagement.<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> Among several different approaches to assess cognitive reserve, we used a questionnaire that assesses a limited number of intellectual activities to ease the telephone interview, but the activities selected are among the most important.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> High cognitive reserve has been found associated with a reduced rate of cognitive decline and dementia.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Prospective longitudinal studies of patients who developed mild cognitive impairment or Alzheimer showed that a higher premorbid cognitive reserve delayed the onset of cognitive decline, although this decline accelerated as soon as the symptoms of dementia started.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> A high educational level, the most commonly assessed cognitive reserve indicator, has been associated with a reduced risk of postoperative cognitive dysfunction or better cognitive outcome after traumatic brain injury.<sup><xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup> Therefore, it is likely that a high cognitive reserve also influences the outcome in patients with anti-LGI1 encephalitis.</p><p>The cognitive deficits of patients with anti-LGI1 encephalitis have been found associated with the presence of residual structural damage to the hippocampus as evaluated by MRI.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> We postulate that patients with bilateral hippocampal MRI abnormalities at disease onset probably have more brain inflammation than those with unilateral lesions or normal MRI and are at risk to eventually develop more severe hippocampal atrophy explaining the association we found with poor cognitive outcome.</p><p>Our study has several limitations. First, we used a transversal design that prevents ascertaining if the long-term cognitive changes result from the acute stage of the encephalitis or from a prolonged, albeit mild, inflammatory activity that contributes to irreversible deficits. Moreover, considering the median age of patients with anti-LGI1 encephalitis, the worsening cognitive status over time of some patients could potentially have been influenced by unrelated comorbidities (e.g., neurodegenerative processes) that were unmasked or aggravated by the autoimmune inflammatory changes. Telephone assessment could only be performed to patients with good familiar support and accessible by phone, which may limit the assessment of institutionalized patients or with advanced dementia downplaying the real impact of anti-LGI1 encephalitis in the cognitive status. Last, we could only explore the cognitive reserve by partially assessing various aspects of life experience but the concept of reserve also accounts for individual differences in susceptibility to age-related brain changes that could not be assessed in this study.<sup><xref rid="R28" ref-type="bibr">28</xref></sup></p><p>A comprehensive evaluation of the long-term outcome of patients with anti-LGI1 encephalitis is essential for a better knowledge of the cognitive domains predominantly affected by the disease and optimal assessment of the efficacy of immunotherapies. We have demonstrated that telemedicine through a structured telephone interview is feasible and provides a good instrument to address these issues. Future studies are encouraged to confirm these results and to validate the brief cognitive battery for its standard use in the evaluation of anti-LGI1 and other autoimmune encephalitis, and it should be considered, along with the mRS, for the long-term assessment of autoimmune encephalitides.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors thank their colleagues for providing clinical information and allowing them to contact the patients included in the study: In&#x000e9;s Barcel&#x000f3; (Hospital Universitario Son Dureta, Palma de Mallorca); Jordi Bruna (Hospital Universitario de Bellvitge, Hospitalet); Dulce Campos (Hospital Universitario de Valladolid, Valladolid); Cesar Ram&#x000f3;n Carbajo (Hospital Universitario Central de Asturias, Oviedo); Crist&#x000f3;bal Carnero (Hospital Universitario Virgen de las Nieves, Granada); Mar Carre&#x000f1;o (Hospital Clinic, Barcelona); Esther Catena (Hospital Universitario de Bellvitge, Hospitalet); Antonio del Olmo (Hospital Universitario Doctor Peset, Valencia); Alfonso Falcon (Hospital San Pedro de Alc&#x000e1;ntara, C&#x000e1;ceres); Jaime G&#x000e1;llego (Cl&#x000ed;nica Universidad de Navarra, Pamplona); Antonio Gil-Nagel (Hospital Ruber Internacional, Madrid); Juan Francisco Gonzalo (Hospital Universitario 12 de Octubre, Madrid); Isabel Illa (Hospital de Sant Pau, Barcelona); Solange Kapetanovic (Hospital Universitario Basurto, Bilbao); M&#x000f3;nica Kurtis (Hospital Ruber Internacional, Madrid); Teresa Lema (Complejo Hospitalario Universitario Juan Canalejo, A Coru&#x000f1;a); Paula Lobato (Complejo Hospitalario de Toledo, Toledo); Jos&#x000e9; Luis Lopez-Sendon (Hospital Universitario Ram&#x000f3;n y Cajal, Madrid); Mercedes Lustres (Complejo Hospitalario Cristal Pi&#x000f1;or, Ourense); Laura Mart&#x000ed;nez (Hospital Virgen del Camino, Pamplona); Jaime Masjuan (Hospital Universitario Ram&#x000f3;n y Cajal, Madrid); Albert Molins (Hospital Universitari Doctor Josep Trueta, Girona); Jaume Morera (Hospital Sant Vicent del Raspeig, Alacant); Alejandro Ponz (Hospital Clinico Universitario de Valencia, Valencia); Silvia Presas (Hospital Germans Trias i Pujol, Badalona); Elsa Puiggr&#x000f2;s (Consorci Sanitari Garraf, Sant Pere de Ribes); Alejandro Quilez (Hospital Universitari Arnau de Vilanova, Lleida); Eloy Rodr&#x000ed;guez (Hospital Universitario Marqu&#x000e9;s de Valdecilla, Santander); Sonia Santos (Hospital Cl&#x000ed;nico Universitario Lozano Blesa, Zaragoza); Carlos Vilar (Hospital General Universitario de Castell&#x000f3;n, Castell&#x000f3;n de la Plana); Alberto Villarejo (Hospital Universitario 12 de Octubre, Madrid); Montserrat Vi&#x000f1;als (Hospital Universitario Reina Sof&#x000ed;a, C&#x000f3;rdoba). They thank Dr. Myrna Rosenfeld for critical reading of the manuscript and useful suggestions.</p></ack><sec sec-type="funding"><title>Study funding</title><p content-type="funding">This study was supported in part by Fondo de Investigaciones Sanitarias and Fondo Europeo de Desarrollo Regional (FEDER), Spain (FIS 15/00377, FG; FIS 14/00203, J.D.), NIH RO1NS077851 (J.D.), and Fundaci&#x000f3; Cellex (J.D.). N. Sola-Valls is a recipient of a Predoctoral Grant for Health Research (FI16/00251) from the Instituto de Salud Carlos III, Spain. H. Ari&#x000f1;o is a recipient of a Rio Hortega grant (CM16/00136) from the Instituto de Salud Carlos III, Spain.</p></sec><sec sec-type="disclosure"><title>Disclosure</title><p content-type="disclosure">N. Sola-Valls received compensation for consulting services and speaker honoraria from Genzyme, Biogen, Merck Serono, and Bayer Schering. H. Ari&#x000f1;o, D. Escudero, E. Solana, and A. Llad&#x000f3; report no disclosures. R. Sanchez-Valle received compensation for consulting services from Ionis Pharmaceuticals, Wave Life Sciences, and Neuraxpharm. Y. Blanco received compensation for consulting services and speaker honoraria from Merck Serono, Biogen Idec, Sanofi-Aventis, Teva, and Novartis. A. Saiz received compensation for consulting services and speaker honoraria from Bayer Schering, Merck Serono, Biogen Idec, Sanofi-Aventis, Teva, Novartis, and Roche. J. Dalmau receives royalties from Athena Diagnostics for the use of Ma2 as an autoantibody test and from Euroimmun for the use of NMDA, GABAB receptor, GABAA receptor, DPPX and IgLON5 as autoantibody tests. He is editor for <italic>Neurology: Neuroimmunology &#x00026; Neuroinflammation</italic>. F. Graus receives royalties from Euroimmun for the use of IgLON5 as an autoantibody test and honoraria for Assistant Editor of MedLink Neurology. Go to <ext-link ext-link-type="uri" xlink:href="https://nn.neurology.org/content/7/2/e652/tab-article-info">Neurology.org/NN</ext-link> for full disclosures.</p></sec><app-group><app id="A1"><label>Appendix</label><title>Authors</title><p><table-wrap id="TU1" orientation="portrait" position="anchor"><graphic xlink:href="NEURIMMINFL2019023820tu1"/><graphic xlink:href="NEURIMMINFL2019023820tu1a"/></table-wrap></p></app></app-group><glossary><title>Glossary</title><def-list><def-item><term id="G1">AUC</term><def><p>area under the curve</p></def></def-item><def-item><term id="G2">FAQ</term><def><p>Functional Activities Questionnaire</p></def></def-item><def-item><term id="G3">LGI1</term><def><p>leucine-rich, glioma-inactivated 1</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Sonderen</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Thijs</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Coenders</surname><given-names>EC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up</article-title>. <source>Neurology</source>
<year>2016</year>;<volume>87</volume>:<fpage>1449</fpage>&#x02013;<lpage>1456</lpage>.<pub-id pub-id-type="pmid">27590293</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irani</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Michell</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>B</given-names></name>, <etal>et al</etal></person-group>
<article-title>Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis</article-title>. <source>Ann Neurol</source>
<year>2011</year>;<volume>69</volume>:<fpage>892</fpage>&#x02013;<lpage>900</lpage>.<pub-id pub-id-type="pmid">21416487</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ari&#x000f1;o</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Armangu&#x000e9;</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Petit-Pedrol</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Anti-LGI1-associated cognitive impairment: presentation and long-term outcome</article-title>. <source>Neurology</source>
<year>2016</year>;<volume>87</volume>:<fpage>759</fpage>&#x02013;<lpage>765</lpage>.<pub-id pub-id-type="pmid">27466467</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finke</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pr&#x000fc;ss</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Heine</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies</article-title>. <source>JAMA Neurol</source>
<year>2017</year>;<volume>74</volume>:<fpage>50</fpage>&#x02013;<lpage>59</lpage>.<pub-id pub-id-type="pmid">27893017</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettcher</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Gelfand</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Irani</surname><given-names>SR</given-names></name>, <etal>et al</etal></person-group>
<article-title>More than memory impairment in voltage-gated potassium channel complex encephalopathy</article-title>. <source>Eur J Neurol</source>
<year>2014</year>;<volume>21</volume>:<fpage>1301</fpage>&#x02013;<lpage>1310</lpage>.<pub-id pub-id-type="pmid">24981998</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butler</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Kaur</surname><given-names>MS</given-names></name>, <etal>et al</etal></person-group>
<article-title>Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex</article-title>. <source>J Neurol Neurosurg Psychiatry</source>
<year>2014</year>;<volume>85</volume>:<fpage>387</fpage>&#x02013;<lpage>391</lpage>.<pub-id pub-id-type="pmid">24403282</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dodich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cerami</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Iannaccone</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis</article-title>. <source>Brain Cogn</source>
<year>2016</year>;<volume>108</volume>:<fpage>81</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">27566001</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roldan-Tapia</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Canovas</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Leon</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Garcia-Garcia</surname><given-names>J</given-names></name></person-group>
<article-title>Cognitive vulnerability in aging may be modulated by education and reserve in healthy people</article-title>. <source>Front Aging Neurosci</source>
<year>2017</year>;<volume>9</volume>:<fpage>340</fpage>.<pub-id pub-id-type="pmid">29118710</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wechsler</surname><given-names>LR</given-names></name>, <name name-style="western"><surname>Tsao</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>SR</given-names></name>, <etal>et al</etal></person-group>
<article-title>Teleneurology applications: report of the telemedicine work group of the American Academy of Neurology</article-title>. <source>Neurology</source>
<year>2013</year>;<volume>80</volume>:<fpage>670</fpage>&#x02013;<lpage>676</lpage>.<pub-id pub-id-type="pmid">23400317</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wadsworth</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Dhima</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Womack</surname><given-names>KB</given-names></name>, <etal>et al</etal></person-group>
<article-title>Validity of teleneuropsychological assessment in older patients with cognitive disorders</article-title>. <source>Arch Clin Neuropsychol</source>
<year>2018</year>;<volume>33</volume>:<fpage>1040</fpage>&#x02013;<lpage>1045</lpage>.<pub-id pub-id-type="pmid">29329363</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bunn</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Burn</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Goodman</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Comorbidity and dementia: a scoping review of the literature</article-title>. <source>BMC Med</source>
<year>2014</year>;<volume>12</volume>:<fpage>192</fpage>.<pub-id pub-id-type="pmid">25358236</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rami</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Valls-Pedret</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bartres-Faz</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Cognitive reserve questionnaire. Scores obtained in a healthy elderly population and in one with Alzheimer's disease</article-title>. <source>Rev Neurol</source>
<year>2011</year>;<volume>52</volume>:<fpage>195</fpage>&#x02013;<lpage>201</lpage>.<pub-id pub-id-type="pmid">21312165</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pfeffer</surname><given-names>RI</given-names></name>, <name name-style="western"><surname>Kurosaki</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Harrah</surname><given-names>CH</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Chance</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Filos</surname><given-names>S</given-names></name></person-group>
<article-title>Measurement of functional activities in older adults in the community</article-title>. <source>J Gerontol</source>
<year>1982</year>;<volume>37</volume>:<fpage>323</fpage>&#x02013;<lpage>329</lpage>.<pub-id pub-id-type="pmid">7069156</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teng</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Knopman</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>PH</given-names></name></person-group>
<article-title>Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease</article-title>. <source>Alzheimer Dis Assoc Dis</source>
<year>2010</year>;<volume>24</volume>:<fpage>348</fpage>&#x02013;<lpage>353</lpage>.</mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Savio</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pietra</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Oddone</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Reggiani</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leone</surname><given-names>MA</given-names></name></person-group>
<article-title>Reliability of the modified Rankin Scale applied by telephone</article-title>. <source>Neurol Int</source>
<year>2013</year>;<volume>5</volume>:<fpage>e2</fpage>.<pub-id pub-id-type="pmid">23717781</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruno</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sethuraman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sedler</surname><given-names>MJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>First application of a Spanish version simplified modified Rankin Scale questionnaire</article-title>. <source>Int J Stroke</source>
<year>2019</year>;<volume>14</volume>:<fpage>NP12</fpage>.<pub-id pub-id-type="pmid">30789320</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garre-Olmo</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lax-Pericall</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Turro-Garriga</surname><given-names>O</given-names></name>, <etal>et al</etal></person-group>
<article-title>Adaptation and convergent validity of a telephone-based Mini-Mental State Examination</article-title>. <source>Med Clin (Barc)</source>
<year>2008</year>;<volume>131</volume>:<fpage>89</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">18590622</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newkirk</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Tinklenberg</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Yesavage</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>JL</given-names></name></person-group>
<article-title>Validation of a 26-point telephone version of the Mini-Mental State Examination</article-title>. <source>J Geriatr Psychiatry Neurol</source>
<year>2004</year>;<volume>17</volume>:<fpage>81</fpage>&#x02013;<lpage>87</lpage>.<pub-id pub-id-type="pmid">15157348</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buschke</surname><given-names>H</given-names></name></person-group>
<article-title>Cued recall in amnesia</article-title>. <source>J Clin Neuropsychol</source>
<year>1984</year>;<volume>6</volume>:<fpage>433</fpage>&#x02013;<lpage>440</lpage>.<pub-id pub-id-type="pmid">6501581</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mrazik</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Millis</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Drane</surname><given-names>DL</given-names></name></person-group>
<article-title>The oral trail making test: effects of age and concurrent validity</article-title>. <source>Arch Clin Neuropsychol</source>
<year>2010</year>;<volume>25</volume>:<fpage>236</fpage>&#x02013;<lpage>243</lpage>.<pub-id pub-id-type="pmid">20197294</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaemmerer</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Riordan</surname><given-names>P</given-names></name></person-group>
<article-title>Oral adaptation of the trail making test: a practical review</article-title>. <source>Appl Neuropsychol Adult</source>
<year>2016</year>;<volume>23</volume>:<fpage>384</fpage>&#x02013;<lpage>389</lpage>.<pub-id pub-id-type="pmid">27218477</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albert</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>DeKosky</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Dickson</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease</article-title>. <source>Alzheimers Dement</source>
<year>2011</year>;<volume>7</volume>:<fpage>270</fpage>&#x02013;<lpage>279</lpage>.<pub-id pub-id-type="pmid">21514249</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zigmond</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Snaith</surname><given-names>RP</given-names></name></person-group>
<article-title>The hospital anxiety and depression scale</article-title>. <source>Acta Psychiatr Scand</source>
<year>1983</year>;<volume>67</volume>:<fpage>361</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">6880820</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buysse</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Reynolds</surname><given-names>CF</given-names><suffix>III</suffix></name>, <name name-style="western"><surname>Monk</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Berman</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Kupfer</surname><given-names>DJ</given-names></name></person-group>
<article-title>The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research</article-title>. <source>Psychiatry Res</source>
<year>1989</year>;<volume>28</volume>:<fpage>193</fpage>&#x02013;<lpage>213</lpage>.<pub-id pub-id-type="pmid">2748771</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devlin</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>R</given-names></name></person-group>
<article-title>EQ-5D and the EuroQol group: past, present and future</article-title>. <source>Appl Health Econ Health Pol</source>
<year>2017</year>;<volume>15</volume>:<fpage>127</fpage>&#x02013;<lpage>137</lpage>.</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>H&#x000e9;bert</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Steriade</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wennberg</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Tang-Wai</surname><given-names>DF</given-names></name></person-group>
<article-title>Long-term cognitive outcomes in patients with autoimmune encephalitis</article-title>. <source>Can J Neurol Sci</source>
<year>2018</year>;<volume>45</volume>:<fpage>540</fpage>&#x02013;<lpage>544</lpage>.<pub-id pub-id-type="pmid">29936915</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teng</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>BW</given-names></name>, <name name-style="western"><surname>Woo</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Cummings</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>PH</given-names></name></person-group>
<article-title>Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment</article-title>. <source>Dement Geriatr Cogn Disord</source>
<year>2010</year>;<volume>30</volume>:<fpage>189</fpage>&#x02013;<lpage>197</lpage>.<pub-id pub-id-type="pmid">20798539</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y</given-names></name></person-group>
<article-title>Cognitive reserve in ageing and Alzheimer's disease</article-title>. <source>Lancet Neurol</source>
<year>2012</year>;<volume>11</volume>:<fpage>1006</fpage>&#x02013;<lpage>1012</lpage>.<pub-id pub-id-type="pmid">23079557</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Stern</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Arenaza-Urquijo</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Bartres-Faz</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>Whitepaper: defining and investigating cognitive reserve, brain reserve, and brain maintenance</article-title>. <source>Alzheimers Dement</source> Epub 2018 Sep 14.</mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matyas</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Keser Aschenberger</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Continuing education for the prevention of mild cognitive impairment and Alzheimer's-type dementia: a systematic review and overview of systematic reviews</article-title>. <source>BMJ Open</source>
<year>2019</year>;<volume>9</volume>:<fpage>e027719</fpage>.</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Loenhoud</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>van der Flier</surname><given-names>WM</given-names></name>, <name name-style="western"><surname>Wink</surname><given-names>AM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Cognitive reserve and clinical progression in Alzheimer disease: a paradoxical relationship</article-title>. <source>Neurology</source>
<year>2019</year>;<volume>93</volume>:<fpage>e334</fpage>&#x02013;<lpage>e346</lpage>.<pub-id pub-id-type="pmid">31266904</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feinkohl</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Winterer</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Spies</surname><given-names>CD</given-names></name>, <name name-style="western"><surname>Pischon</surname><given-names>T</given-names></name></person-group>
<article-title>Cognitive reserve and the risk of postoperative cognitive dysfunction</article-title>. <source>Dtsch Arztebl Int</source>
<year>2017</year>;<volume>114</volume>:<fpage>110</fpage>&#x02013;<lpage>117</lpage>.<pub-id pub-id-type="pmid">28302254</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bigler</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Stern</surname><given-names>Y</given-names></name></person-group>
<article-title>Traumatic brain injury and reserve</article-title>. <source>Handb Clin Neurol</source>
<year>2015</year>;<volume>128</volume>:<fpage>691</fpage>&#x02013;<lpage>710</lpage>.<pub-id pub-id-type="pmid">25701915</pub-id></mixed-citation></ref></ref-list></back></article>